Genetic Complexity of Crohns Disease in 2 Large Ashkenazi Jewish Families

Supplementary Information

Adam P. Levine, Nikolas Pontikos, Elena R. Schiff, Luke Jostins, Doug Speed, NIDDK Inflammatory Bowel Disease Genetics Consortium, Laurence B. Lovat, Jeffrey C. Barrett, Helmut Grasberger, Vincent Plagnol and Anthony W. Segal

Correspondence: t.segal@ucl.ac.uk
1 Supplementary Methods

1.1 Ancestry assessment

The Ashkenazi Jewish (AJ) ancestry of all individuals was confirmed by principal component analysis (PCA) using snpStats (v1.14.0 [1]) with a reference dataset of 471 unrelated individuals with four AJ grandparents [2] and non-Jewish populations (CEU (Utah residents with North and Western European ancestry) and TSI (Toscani in Italy)) from HapMap [3]. Related individuals and poorly genotyped samples and SNPs were removed. Common SNPs were extracted and pruned for LD ($r^2 < 0.2$) in each dataset separately.

1.2 Marker set for linkage analysis

AJ specific RAFs for linkage were obtained using SNP data in 1,502 individuals of AJ ancestry, confirmed by PCA (as above) and extracted from a larger cohort on dbGAP [4] (phs000448.v1.p1) [5]. SNPs shared with those genotyped in the families were pruned for LD in the reference data at $r^2 < 0.2$. The heterozygosity and RAF were computed using PLINK and the SNP with the highest heterozygosity sequentially within sliding windows of 0.1 and 0.5 cM were selected for the linkage map using a custom Python script.

1.3 Linkage analysis

Linkage analysis was performed using Switflink. To account for the unknown disease penetrance, only affected individuals were considered. The Switflink MCMC was parallelised on four core-processors using default parameters and the average of ten replicates taken.

1.4 Samples used for exome sequencing

In addition to the affected individuals from the families, exome sequencing was undertaken on from a selection of unaffected family members and AJ controls. Specifically, in Family A, 23 unaffected family members were sequenced comprising eight non-founder parents of affected individuals, six founders with no affected children and nine founders with one or more affected children. In Family B, 18 unaffected family members were sequenced comprising two non-founder parents of affected individuals, four founders...
The genetics of Crohn’s disease
in two large Ashkenazi Jewish families

Levine AP, et al.

with one or more affected children and 12 unaffected siblings or cousins of
affected individuals. In addition, 31 unrelated AJ controls were sequenced.

1.5 Haplotype flow reconstruction

The full pedigrees, a total of 322 individuals in Family A and 132 individuals
in Family B were manually divided into non-overlapping subfamilies of
≤ 28 bits (twice the number of founders minus the number of non-founders)
such that each subfamily was within the computational capabilities of Mer-
lin [6]. For Family A there were 21 subfamilies and for Family B, seven.
Within each subfamily, the most likely pattern of gene flow was estimated
by Merlin using the 0.1 cM SNP map. For each non-founder within each
subfamily, the founder source of each allele for each marker was thus deter-
mined. However, as the maternal/paternal classification of founder alleles
is random (as the parents are unobserved) reassembling the split haplotype
flow data is not straightforward. This is further complicated when founders
are ungenotyped. To achieve haplotype founder source matching, hypothe-
ses representing the different haplotype matching scenarios may be tested
by comparing the sum of the observed probabilities of identical-by-descent
inheritance for all individuals sharing each haplotype for each marker with
that expected assuming they do indeed match. Pairwise identical-by-descent
probabilities for each marker were estimated across all pairs of individuals
in each full pedigree using a multiple splitting approach similar to that
described by Thomson et al. [7]. Sub-pedigrees for all $x(x - 1)/2$ pairs
of individuals across the entire (pre-split) pedigree containing just the two
individuals of interest, one genotyped sibling (if available, to assist with
phasing) and their connecting ancestral relatives were generated; a total
of 33,411 sub-pedigrees for Family A and 4,465 for Family B. Identical-by-
descent probabilities using these sub-pedigrees were estimated using Merlin.
In cases in which pairs of individuals appeared in multiple sub-pedigrees,
the average identical-by-descent probabilities per marker across all observa-
tions of that pair of individuals was computed. Utilising these probabili-
ties, haplotype matching was performed across the subfamilies progressively
building up by adding one subfamily at a time. The maximum number of
affected individuals sharing a founder haplotype within a particular family
or subfamily was subsequently computed. These results were verified using
Combinatorial Conflicting Homozygosity analysis [8].

1.6 Within-family imputation

For each variant, the imputation proceeded by first assigning the founder
haplotypes for all wild type and homozygote individuals as reference and
alternate, respectively. Next, all heterozygote individuals were considered and if one of their founder haplotypes was reference or alternate, the other founder haplotype was assigned as the opposite, respectively. For each variant, this was repeated until no more founder haplotypes were updated. Consistency checks were performed at each step to verify that the two founder haplotypes and genotypes for each individual were compatible. If the allele frequency of the variant in ExAC and in the AJ control data (AJex) was <0.01, it was assumed that unobserved founder haplotypes would be wild type for the variant. Finally, the genotypes of all individuals for which both founder haplotypes were known were imputed. A similar approach has been described by Song et al. [9]. When an imputation conflict arose (in which the imputed genotype differed from that observed by direct genotyping for those individuals from whom it was available or when a haplotype was assigned as harbouring both the reference and alternate alleles), all imputed genotypes for that variant were discarded and only the genotypes in those individuals directly sequenced or genotyped were retained.

1.7 Candidate variant genotyping

The DUOX2 and CSF2RB variants were genotyped in a selection of sequenced and imputed individuals for validation purposes. This was done by Sanger sequencing following PCR amplification of the flanking sequence. For the CSF2RB variant (chr22:37333972 GC/G, p.S709LX22), the forward primer was GTGGGAGGACAGGACCAAAA and the reverse was GGAACTAGGGAGACAGACG yielding a product of 150 bp. For the DUOX2 variant (chr15:45402883 G/C, rs151261408, p.P303R), the forward primer was GCTGGAGAGATTTCCCTACTAAGC and the reverse primer was TCCTGTCTGAGTTGCTTCTCC yielding a product of 600 bp. In both cases, PCR was conducted using an annealing temperature of 60°C.

1.8 DUOX2 functional experiments

1.8.1 Plasmids

The c.908C>G (p.P303R) DUOX2 variant was introduced into an N-terminal hemagglutinin epitope (HA)-tagged DUOX2 expression vector [10] by site-directed mutagenesis (QuikChange; Stratagene, La Jolla, CA) (sense primer: 5’-CTGTGATGATGGCTGCGAGCTTCTGAGAGAAAACG-3’). To generate expression vectors for FLAG-epitope tagged 303P and 303R DUOX2, the HA-tag was replaced by a FLAG (DYKDDDDK) encoding sequence using the splicing-by-overlap PCR technique with either 303P or 303R HA-DUOX2 plasmids as template. Internal primers in the first-round PCR reac-
The genetics of Crohn’s disease in two large Ashkenazi Jewish families
Levine AP, et al.

1.8.2 Cell culture and transfection

HEK 293 were maintained in DMEM (Life Technologies, Carlsbad, CA, USA) supplemented with 10% heat inactivated fetal bovine serum. Adherent cells were transfected at 50-60% confluence using FuGENE 6 reagent (Promega, Madison, WI, USA). Plasmids encoding DUOX2 maturation factor (either DUOXA2 or DUOXA2-EGFP) were cotransfected at 13 ng/cm² of cell monolayer, whereas the amount of DUOX2 encoding plasmids was varied from 2.1-21 ng/cm². Under these conditions, DUOXA2 is available in significant excess and does not limit DUOX2/DUOXA2 heterodimerization [11,12]. In all experiments, the total amount of DNA transfected per square centimeter of cell monolayer was kept constant by adjusting with empty pcDNA3.1 vector.

1.8.3 Hydrogen peroxide production assay

Release of hydrogen peroxide was determined by reaction with cell-impermeable 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red reagent; Life Technologies) in the presence of excess peroxidase, producing fluorescent resorufin. Briefly, cell monolayers in 24-well plates were incubated in HBSS/10 mM Hepes (pH 7.4) supplemented with 50 µM Amplex Red reagent and 0.1 U/ml horseradish peroxidase for one hour at 37°C. For stimulation of DUOX2 NADPH-oxidase activity, ionomycin (1 µM) and 12-O-tetradecanoylphorbol-13-acetate (TPA; 400 nM) were included in the reaction buffer. Fluorescence (ex/em, 530/595 nm) of the medium was measured within the linear range of the hydrogen peroxide concentration response curve and corrected for Amplex Red oxidation in wells containing cells transfected with empty pcDNA3.1 vector only. As internal control for transfection efficiency, Renilla luciferase activity from cotransfected pRL-Tk plasmid (2 ng/well) was determined in the remaining cells.
1.8.4 **Superoxide release assay**

Extracellular superoxide release of cells resuspended in Krebs-Ringer-HEPES buffer (pH 7.4) was detected using Diogenes reagent (National Diagnostics, Atlanta, GA, USA). Chemiluminescence was recorded following the addition of TPA/ionomycin to $2 \times 10^5$ cells/200 µl reaction. Cells co-transfected with DUOX2 and DUOXA1 plasmids were used as positive control for $O_2^-$ release [13,14]. Specificity of the assay for superoxide was ascertained by including superoxide dismutase (10 µg/ml) in parallel reactions.

1.8.5 **Flow cytometry**

To detect surface-expressed epitopes, cells were washed twice in PBS, and incubated for 30 min (15 min at room temperature, 15 min on ice) with either rat anti-HA (0.5 ng/µl of clone 3F10, Roche) or mouse anti-FLAG (1 ng/µl of clone M2; Sigma) diluted in HBSS/10 mM HEPES pH 7.4/1% BSA. Cells were washed twice in cold PBS, detached in 2 mM EDTA and fixed at 4°C in 0.75% formaldehyde. Bound antibodies were detected using Alexa Fluor 647-conjugated anti-rat or anti-mouse IgG, respectively. Cytometry data for 100,000 events per sample were acquired on a BD Accuri C6 Flow Cytometer (BD Biosciences) and appropriate FSC/SSC gates were employed to exclude cellular debris. Data were analyzed using FlowJo 8.8.7 software. Relative surface expression of DUOX2 was determined by calculating differences in total fluorescence intensity between the samples and an equal-sized population of control cells overexpressing DUOX2 but not its maturation factor. Without the latter, DUOX2 could not be detected in non-permeabilized cells (Figure 4D). For detection of intracellular DUOX2, detached cells were first fixed in 0.75% formaldehyde/PBS at 4°C, then washed and permeabilized with 0.2% saponin in PBS/0.1% BSA. Binding of antibodies was done as above, but in the presence 0.2% saponin. Total DUOX2 expression was determined by calculating differences in total fluorescence intensity between the samples and an equal-sized population of control cells transfected with empty pcDNA3.1 plasmid. To test whether expression of the 303R variant interferes specifically with the surface expression of wild type (303P) DUOX2, cells were transfected with equal amounts of HA-tagged and FLAG-tagged DUOX2 constructs of either the 303P and/or 303R variants and the surface expression of the HA-tagged variant determined under each condition. Surface expression of the FLAG-tagged DUOX2 constructs is depicted in Supplementary Figure 4.
2 Supplementary Figures

Figure S1: Principal component analysis showing the distinct separation of a reference panel of Ashkenazi Jewish (AJ) individuals from North and West European (CEU) and Tuscan (TSI) HapMap populations and the clustering of samples from the two families with the reference AJ population.
Figure S2: Genetic risk scores (GRS) in affected and unaffected individuals in Family A grouped by subfamily (labelled 0 through to 5). Unaffected individuals have been divided into those with (+aFiDR) and without (-aFiDR) at least one affected first degree relative.
Figure S3: Chemiluminescence assay for superoxide (O$_2^-$) generation by the 303R-DUOX2 variant. Extracellular superoxide release was recorded following stimulation with TPA. As a positive control, DUOX2 was coexpressed with DUOXA1 to produce an unstable enzyme complex prone to O$_2^-$ leakage [7,8]. 303R-DUOX2/DUOXA2 does not release detectable level of O$_2^-$ consistent with normal dismutation of O$_2^-$ to H$_2$O$_2$ within the enzyme complex. Data shown are from a single experiment and representative for the results of three independent experiments.
Figure S4: Cell surface expression of recombinant DUOX2 variants detected using HA (A) or FLAG (B) epitopes. Surface expression in transfected HEK293 cells was determined by flow cytometry of non-permeabilized cells. For each experiment, the values for the 303R-DUOX2 variant were normalized to those for wild type (303P) DUOX2 (set to 100%). Bars indicate mean(± SD) from n=4 independent transfection experiments. *** p<0.001, ** p<0.01 (ratio paired t-test).
3 Supplementary Table Legends

Supplementary Table 1
Association analysis (correcting for relatedness) results for 127 CD-associated risk variants in Family A and Family B. Column headers are as follows:

**rsID**: dbSNP identifier, **CHR**: chromosome, **BP**: genome position (Build 37), **RiskAllele**: Crohn’s disease associated risk allele, **OR**: published odds ratio (see main paper for source), **Freq**: published frequency of the risk allele in controls (see main paper for source), **A_ControlFreq**: frequency of risk variant in unaffected individuals in Family A, **A_CaseFreq**: frequency of risk variant in affected individuals in Family A, **A_P**: LDAK p-value for Family A, **B_ControlFreq**: frequency of risk variant in unaffected individuals in Family B, **B_CaseFreq**: frequency of risk variant in affected individuals in Family B, **B_P**: LDAK p-value for Family B.

Supplementary Table 2
Exome variants prioritised in Family A (n=66). Column headers are defined in Table 1 of this document. The frequency of the variant in affected and unaffected individuals, LDAK p-value and direction of effect are shown for the family overall and for subfamilies A0, A1 and A2.

Supplementary Table 3
Exome variants prioritised in Family B (n=11). See legend for Supplementary Table 2.
### Table 1: Definitions of columns in Supplementary Tables 2 and 3

| Field          | Definition                                           |
|----------------|------------------------------------------------------|
| CHR            | Chromosome                                           |
| POS            | Genome positions (Build 37)                          |
| REF            | Reference allele                                     |
| ALT            | alternative allele                                   |
| ID             | rs ID, if available                                  |
| Gene           | Ensembl gene identifier                              |
| Feature        | Ensembl transcript identifier(s)                     |
| Consequence    | Variant consequence                                 |
| cDNA_pos       | cDNA position of alteration                          |
| Protein_pos    | Protein position of alteration                        |
| Amino_acids    | Amino acid change                                    |
| SYMBOL         | Gene symbol                                          |
| CAROL          | deleteriousness prediction                           |
| Condel         | deleteriousness prediction                           |
| CADD           | deleteriousness prediction                           |
| EXAC_Adj       | ExAC composite allele frequency                      |
| ImmunoBase_CRO | Crohn’s disease GWAS loci                            |
| UCLEX          | UCLEX allele frequency                               |
| BroadAJControls| AJex control Ashkenazi Jewish allele frequency        |
| ONEGK_EUR      | 1000 Genomes, European allele frequency              |
| freq cases     | frequency in cases in the family (or subfamily)      |
| freq controls  | frequency in controls in the family (or subfamily)   |
| effect         | direction of effect in the family (or subfamily)     |
| P              | LDAK p-value in the family (or subfamily)            |
| minP           | Minimum p-value observed (A only)                    |
| family         | Subfamily/family in which minP was observed (A only)  |
| CONFLICT       | Number of imputation conflicts observed              |
| AJex_control_AF| AJex control allele frequency                        |
| AJex_case_AF   | AJex case allele frequency                           |
| AJex_OR        | AJex odds ratio                                      |
| AJex_p         | AJex p-value                                         |
4 References

1. Clayton D, Leung H-T. An R package for analysis of whole-genome association studies. Hum. Hered. 2007;64:4551.

2. Bray SM, Mulle JG, Dodd AF, et al. Signatures of founder effects, admixture, and selection in the Ashkenazi Jewish population. Proc. Natl. Acad. Sci. U. S. A. 2010;107:1622216227.

3. Altshuler DM, Gibbs RA, Peltonen L, et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010;467:528.

4. Tryka KA, Hao L, Sturcke A, et al. NCBIs Database of Genotypes and Phenotypes: dbGaP. Nucleic Acids Res. 2014;42:D9759.

5. Guha S, Rosenfeld JA, Malhotra AK, et al. Implications for health and disease in the genetic signature of the Ashkenazi Jewish population. Genome Biol. 2012;13:R2.

6. Abecasis GR, Cherny SS, Cookson WO, et al. Merlin–rapid analysis of dense genetic maps using sparse gene flow trees. Nat. Genet. 2002;30:97101.

7. Thomson R, Quinn S, McKay J, et al. The advantages of dense marker sets for linkage analysis with very large families. Hum. Genet. 2007;121:459468.

8. Levine AP, Connor TMF, Oygar DD, et al. Combinatorial Conflict- ing Homozygosity (CCH) analysis enables the rapid identification of shared genomic regions in the presence of multiple phenocopies. BMC Genomics. 2015;16:163.

9. Song S, Shields R, Li X, et al. Joint analysis of sequence data and single-nucleotide polymorphism data using pedigree information for imputation and recombination inference. BMC Proc. 2014;8:S20.

10. Grasberger H, Refetoff S. Identification of the maturation factor for dual oxidase. Evolution of an eukaryotic operon equivalent. The Journal of Biological Chemistry. 2006; 281:18269-72

11. Grasberger H, De Deeken X, Miot F, Pohlenz J, Refetoff S. Missense mutations of dual oxidase 2 (duox2) implicated in congenital hypothyroidism have impaired trafficking in cells reconstituted with duox2 maturation factor. Molecular Endocrinology. 2007;21:1408-21

12. Rigutto S, Hoste C, Grasberger H, Milenkovic M, Communi D, Dumont JE, Corvilain B, Miot F, De Deeken X. Activation of dual oxidases duox1 and duox2: Differential regulation mediated by camp-dependent
The genetics of Crohn’s disease in two large Ashkenazi Jewish families
Levine AP, et al.

protein kinase and protein kinase c-dependent phosphorylation. The Journal of Biological Chemistry. 2009;284:6725-34

13. Zamproni I, Grasberger H, Cortinovis F, Vigone MC, Chiumello G, Mora S, Onigata K, Fugazzola L, Refetoff S, Persani L, Weber G. Biallelic inactivation of the dual oxidase maturation factor 2 (duoxa2) gene as a novel cause of congenital hypothyroidism. The Journal of Clinical Endocrinology and Metabolism. 2008;93:605-10

14. Morand S, Ueyama T, Tsujibe S, Saito N, Korzeniowska A, Leto TL. Duox maturation factors form cell surface complexes with duox affecting the specificity of reactive oxygen species generation. FASEB Journal.2009;23:1205-18